The Journal of Practical Medicine >

2024 , Vol. 40 >Issue 7: 966 - 971

DOI: https://doi.org/10.3969/j.issn.1006-5725.2024.07.015

Clinical Research

The predictive value of 18F⁃FDG PET/CT metabolic heterogeneity parameters combined with clinical features for the prognosis of esophageal squamous cell carcinoma before definitive radiochemotherapy

  • Xiya MA ,
  • Hu JI ,
  • Zehua ZHU ,
  • Bo PAN ,
  • Qiang XIE ,
  • Xiaobo. YAO
Expand
  • Graduate School of Bengbu Medical University，Bengbu 233000，China

Received date: 2023-09-21

  Online published: 2024-04-08

Fold

Abstract

Objective This study aimed to explore the prognostic value of 18F?FDG PET/CT Metabolic and Heterogeneity Parameters Combined with Clinical Features Before Definitive Chemoradiotherapy （D?CRT） in predicting the prognosis of esophageal squamous cell carcinoma （ESCC） Patients. Methods A retrospective analysis was conducted on clinical data from 106 patients with ESCC who received D?CRT at the first affiliated Hospital of University of Science and Technology of China between January 2017 and December 2021. All patients underwent 18F?FDG PET/CT examination before the treatment. The primary tumor's metabolic and heterogeneity parameters were obtained through data processing. All patients were followed up for overall survival. The Kaplan?Meier method and Cox proportional hazards models were used to analyze the association between clinical features， tumor metabolism and heterogeneity parameters and patient prognosis. Results The 1? and 1.5?year overall survival rates of all patients were 77.4%and 51.9%. The median survival time was 20 months. Univariate analysis showed that N stage， M stage， metabolic tumor volume， total lesion glycolysis， heterogeneity index?2 （HI?2）， and coefficient of variation with a threshold of 40% maximum standard uptake value （CV40%） were correlated with the prognosis of ESCC （all P< 0.05）. Multivariate analysis showed that N stage and CV40% were independent predictors of prognosis in patients with ESCC （P = 0.039 and P < 0.001， respectively）. Conclusion N stage and tumor metabolic heterogeneity parameter CV40%， which offering a degree of predictive value， are closely related to the prognosis of patients with ESCC treated with D?CRT.

Key words： esophageal squamous cell carcinoma; intra?tumor metabolic heterogeneity; intensity?modulated radiotherapy; PET/CT; prognosis

Cite this article

Xiya MA , Hu JI , Zehua ZHU , Bo PAN , Qiang XIE , Xiaobo. YAO . The predictive value of 18F⁃FDG PET/CT metabolic heterogeneity parameters combined with clinical features for the prognosis of esophageal squamous cell carcinoma before definitive radiochemotherapy[J]. The Journal of Practical Medicine, 2024 , 40(7) : 966 -971 . DOI: 10.3969/j.issn.1006-5725.2024.07.015

References

1 SHEN D H Y， CHAN H P， TSAI F R， et al. Prognostic Value of 18F-FDG PET/CT Volume-Based Metabolic Parameters in Patients with Node-Negative Stage II Esophageal Squamous Cell Carcinoma［J］. Metabolites， 2021， 12（1）： 7. doi:10.3390/metabo12010007
2 ALOTAIBI A， GADEKAR V P， GUNDLA P S， et al. Global comparative transcriptomes uncover novel and population-specific gene expression in esophageal squamous cell carcinoma［J］. Infect Agent Cancer， 2023，18（1）：47. doi:10.1186/s13027-023-00525-8
3 中国医师协会放射肿瘤治疗医师分会， 中华医学会放射肿瘤治疗学分会， 中国抗癌协会肿瘤放射治疗专业委员会. 中国食管癌放射治疗指南（2021年版）［J］. 国际肿瘤学杂志， 2022， 49（1）：14. doi:10.3760/cma.j.cn371439-20211021-00002
4 邱云亮， 郭喆， 孙晋， 等. 18F-FDG PET/CT代谢参数预测老年食管鳞癌预后的价值［J］. 中国医学影像学杂志， 2021， 29（10）： 998-1002. doi:10.3969/j.issn.1005-5185.2021.10.009
5 LIU X， ZHANG Y F， SHI Q， et al. Prediction value of 18F-FDG PET/CT intratumor metabolic heterogeneity parameters for recurrence after radical surgery of stage Ⅱ/Ⅲ colorectal cancer［J］. Front Oncol， 2022， 12： 945939. doi:10.3389/fonc.2022.945939
6 LIU G， YIN H， CHENG X， et al. Intra-tumor metabolic heterogeneity of gastric cancer on 18 F-FDG PETCT indicates patient survival outcomes［J］. Clin Exp Med， 2021，21（1）：129-138. doi:10.1007/s10238-020-00659-8
7 JO J H， CHUNG H W， SO Y， et al. FDG PET/CT to predict recurrence of early breast invasive ductal carcinoma［J］. Diagnostics， 2022， 12（3）： 694. doi:10.3390/diagnostics12030694
8 NI M， WANG S， LIU X， et al. Predictive value of intratumor metabolic and heterogeneity parameters on ［18F］ FDG PET/CT for EGFR mutations in patients with lung adenocarcinoma［J］. Jpn J Radiol， 2023，41（2）：209-218. doi:10.1007/s11604-022-01347-1
9 中国非手术治疗食管癌临床分期专家小组. 非手术治疗食管癌的临床分期标准（草案） ［J］. 中华放射肿瘤学杂志， 2010， 19（3）： 179-180. doi:10.3760/cma.j.issn.1004-4221.2010.03.001
10 METZGER J C， WOLLSCHL?GER D， MIEDERER M， et al. Inclusion of PET-CT into planning of primary or neoadjuvant chemoradiotherapy of esophageal cancer improves prognosis［J］.Strahlenther Onkol， 2017， 193（10）： 791. doi:10.1007/s00066-017-1164-3
11 于珺，李永顺，黄长荣，等. FDG PET/CT代谢体积对食管癌术后预后的预测价值［J］. 影像研究与医学应用， 2018，2（21）：193-194. doi:10.3969/j.issn.2096-3807.2018.21.130
12 戴亮，付浩，王菲，等. 食管鳞癌原发肿瘤正电子发射计算机断层显像的最大标准摄取值与术后生存相关分析［J］. 中华医学杂志， 2018，98（21）：1707-1712. doi:10.3760/cma.j.issn.0376-2491.2018.21.017
13 MARTíNEZ A， INFANTE J R， QUIRóS J， et al. Baseline 18F-FDG PET/CT quantitative parameters as prognostic factors in esophageal squamous cell cancer［J］. Rev Esp Med Nucl Imagen Mol （Engl Ed）， 2022，41（3）：164-170. doi:10.1016/j.remnie.2021.07.006
14 LI Y， HOFHEINZ F， FURTH C， et al. Increased evidence for the prognostic value of FDG uptake on late-treatment PET in non-tumour-affected oesophagus in irradiated patients with oesophageal carcinoma［J］. Eur J Nucl Med Mol Imaging， 2018， 45（10）： 1752-1761. doi:10.1007/s00259-018-3996-1
15 YUAN Y. Spatial heterogeneity in the tumor microenvironment［J］. Cold Spring Harb Perspect Med， 2016，6（8）：a026583. doi:10.1101/cshperspect.a026583
16 ZHU L， JIANG M， WANG H， et al. A narrative review of tumor heterogeneity and challenges to tumor drug therapy［J］. Ann Transl Med， 2021，9（16）：1351. doi:10.21037/atm-21-1948
17 KIM Y， KIM Y J， PAENG J C， et al. Heterogeneity index evaluated by slope of linear regression on 18F-FDG PET/CT as a prognostic marker for predicting tumor recurrence in pancreatic ductal adenocarcinoma［J］. Eur J Nucl Med Mol Imaging， 2017，44（12）：1995-2003. doi:10.1007/s00259-017-3755-8
18 KIM T H， YOON J K， KANG D K， et al. Correlation between F-18 fluorodeoxyglucose positron emission tomography metabolic parameters and dynamic contrast-enhanced MRI-derived perfusion data in patients with invasive ductal breast carcinoma［J］.Ann Surg Oncol， 2015，22（12）：3866-3872. doi:10.1245/s10434-015-4526-z
19 CHUNG H H， KANG S Y， HA S， et al. Prognostic value of preoperative intratumoral FDG uptake heterogeneity in early stage uterine cervical cancer［J］. J Gynecol Oncol， 2016， 27（2）： e15. doi:10.3802/jgo.2016.27.e15
20 DONG X， XING L， WU P， et al. Three-dimensional positron emission tomography image texture analysis of esophageal squamous cell carcinoma： relationship between tumor： 18： F-fluorodeoxyglucose uptake heterogeneity， maximum standardized uptake value， and tumor stage［J］. Nucl Med Commun， 2013，34（1）：40-46. doi:10.1097/mnm.0b013e32835ae50c
21 GOPAL A， XI Y， SUBRAMANIAM R M， et al. Intratumoral Metabolic Heterogeneity and Other Quantitative 18F-FDG PET/CT Parameters for Prognosis Prediction in Esophageal Cancer［J］.Radiol Imaging Cancer， 2020， 3（1）： e200022. doi:10.1148/rycan.2020200022
Options
Outlines

/

〈 〉